Friday, September 4, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways

View original at finance.yahoo.com
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways MEDVI Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists Compounded Options Alongside New FDA-Approved Oral Pathway Los Angel…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Limited-time savings offer for oral Wegovy starting dose at approximately $149 per month

    80% confidence

  • MEDVi-affiliated medical professional entities are not contracted healthcare providers with any health insurance plans

    80% confidence

  • Limited-time cash-pay savings offer for Wegovy injection at $199 for initial doses, then $349 thereafter

    80% confidence

  • MEDVi does not provide any Healthcare Services through the Platform and is not licensed to practice medicine

    80% confidence

  • The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed

    80% confidence

  • OASIS 4 trial showed approximately 13-14% average weight loss over 64 weeks with oral Wegovy, with up to 16.6% among adherent participants

    80% confidence

  • STEP 1 trial demonstrated 14.9% average body weight loss over 68 weeks with Wegovy injection

    80% confidence

  • Novo Nordisk plans a full U.S. launch of oral Wegovy in early January 2026

    80% confidence

  • Compounded semaglutide in multi-dose vials can create dosing confusion, especially when instructions use 'units' rather than mg/mL measurements, leading to overdoses in some reported cases

    80% confidence

  • FDA is not aware of a basis for compounding using salt forms such as semaglutide sodium or semaglutide acetate

    80% confidence

  • Payment does not guarantee the writing or dispensing of a prescription

    80% confidence

  • FDA received reports of adverse events including hospitalizations that may be related to dosing errors with compounded semaglutide products

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways — Source | Via News | Via News